Exhibit 1
Top Alliances In February 2012
Deals In Depth: February 2012
Pfizer and Zhejiang Hisun Pharmaceutical together invested $545 million to create a Chinese generics joint venture. Dainippon Sumitomo Pharma expanded its cancer pipeline though the acquisition of Boston Biomedical. Driven by a large amount of FOPOs, biopharma financing totaled $1.8 billion in February, while device companies raised $248 million.
More from Deal-Making
More from In Vivo
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.